Advertisement

Topics

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

07:28 EDT 17 Apr 2018 | PMLIVE

Data shows the combo can improve survival compared to Pfizer’s Sutent

Original Article: BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

NEXT ARTICLE

More From BioPortfolio on "BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...